Replies to post #245865 on Biotech Values

[DewDiligence]

Re: PFE-SGEN opinion

As a PFE shareholder I would have preferred that PFE buy back its own (undervalued) stock rather than spend $43B on an acquisition. Still, this deal may work out well if SGEN can continue to develop best-in-class ADCs based on the company's proprietary linker technology. ADC's have potential application in a large number of cancer indications where traditional chemotherapy is still part of the SoC.

[DewDiligence]

PFE sells $31B of_debt_in_8 tranches—to fund SGEN acquisition:

https://www.businesswire.com/news/home/20230516005960/en/

• $3B of 2-yr notes @4.65%

• $3B of 3-yr notes @4.45%

• $4B of 5-yr notes @4.45%

• $3B of 7-yr notes @4.65%

• $5B of 10-yr notes @4.75%

• $3B of 20-yr notes @5.11%

• $6B of 30-yr notes @5.30%

• $4B of 40-yr(!) notes @5.34%

[DewDiligence]

SGEN shareholders overwhelmingly approve acquisition by PFE:

https://www.businesswire.com/news/home/20230530005610/en